Alvotech Differentiation Plans Include Interchangeable Golimumab
Icelandic Company Details Strategy Amid Proposed SPAC Merger
A proposal to merge with a special purpose acquisition company, in a move that will deliver longstanding plans for a public listing, has led biosimilars specialist Alvotech to discuss its ambitions and goals for its pipeline of seven biosimilar candidates.
You may also be interested in...
Alvotech and AbbVie have settled all of their legal disputes over Alvotech’s AVT02 biosimilar rival to Humira. With Alvotech seeking a coveted interchangeability designation for its higher-strength adalimumab, the firm’s US entry date provided by the settlement matches that of Boehringer Ingelheim’s interchangeable Cyltezo lower-strength adalimumab biosimilar.
Ahead of the first biosimilar Humira product set to launch in less than a year, In Vivo provides a comprehensive run-down of where biosimilar sponsors stand and the key issues ahead of market formation.
Alvotech and Fuji Pharma have extended their strategic alliance for the commercialization of Alvotech biosimilars in Japan, adding a further early-stage candidate to the list of products covered by the deal that now encompasses six biosimilars.